Latest GANX ETF News Today | Earnings, Events & Price Alerts

GANX News

Gain Therapeutics Attends J.P. Morgan Healthcare Conference to Showcase GT-02287

Jan 07 2026Globenewswire

GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement

Jan 05 2026Benzinga

Gain Therapeutics Hosts KOL Event on Parkinson's Disease Biomarkers and GT-02287

Dec 18 2025Globenewswire

Gain Therapeutics Hosts KOL Event on Parkinson's Disease Biomarkers and GT-02287

Dec 18 2025Newsfilter

Gain Therapeutics Demonstrates GT-02287's Positive Impact on Parkinson's Disease for the First Time

Dec 18 2025Newsfilter

Reasons to Consider Gain Therapeutics, Inc. (GANX) as a Strong Momentum Stock Investment

Dec 08 2025NASDAQ.COM

Gain Therapeutics (GANX) Receives Upgrade to Buy: Key Information You Need to Know

Nov 17 2025NASDAQ.COM

Gain Therapeutics Reports GAAP EPS of -$0.15, Exceeding Expectations by $0.01

Nov 12 2025SeekingAlpha

Gain Therapeutics to Hold Virtual KOL Event Focused on GT-02287 for Parkinson's Disease

Oct 09 2025Newsfilter

Gain Therapeutics to Take Part in the 2025 Drug Discovery Innovation Program

Sep 23 2025Newsfilter

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Jul 24 2025Newsfilter

US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus

Jul 16 2025Benzinga

Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket

Jul 16 2025Benzinga

Gain Therapeutics announces proposed public offering

Jul 15 2025SeekingAlpha

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

Jul 03 2025Benzinga

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Jun 30 2025Newsfilter

GANX

GANX

GANX News

Gain Therapeutics Attends J.P. Morgan Healthcare Conference to Showcase GT-02287

GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement

Gain Therapeutics Hosts KOL Event on Parkinson's Disease Biomarkers and GT-02287

Gain Therapeutics Hosts KOL Event on Parkinson's Disease Biomarkers and GT-02287

Gain Therapeutics Demonstrates GT-02287's Positive Impact on Parkinson's Disease for the First Time

Reasons to Consider Gain Therapeutics, Inc. (GANX) as a Strong Momentum Stock Investment

Gain Therapeutics (GANX) Receives Upgrade to Buy: Key Information You Need to Know

Gain Therapeutics Reports GAAP EPS of -$0.15, Exceeding Expectations by $0.01

Gain Therapeutics to Hold Virtual KOL Event Focused on GT-02287 for Parkinson's Disease

Gain Therapeutics to Take Part in the 2025 Drug Discovery Innovation Program

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus

Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket

Gain Therapeutics announces proposed public offering

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson&#39;s Disease With or Without a GBA1 Mutation

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation